Sterilizing effect of ertapenem-clavulanate in a hollow-fiber model of tuberculosis and implications on clinical dosing

Antimicrobial Agents and Chemotherapy

Volumn 61, Issue 9, 2017, Pages

  Van Rijn, Sander P ^a   Srivastava, Shashikant ^b   Wessels, Mireille A ^a   Van Soolingen, Dick ^c,d   Alffenaar, Jan Willem C ^a   Gumbo, Tawanda ^b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b BAYLOR RESEARCH INSTITUTE   (United States)

^c NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Ertapenem; Hollow fiber infection model; MDR TB; Mycobacterium tuberculosis; Pharmacodynamics; Pharmacokinetics

Indexed keywords

BETA LACTAM; CLAVULANIC ACID; ERTAPENEM; TUBERCULOSTATIC AGENT;

COMBINATION DRUG THERAPY; COMPUTER SIMULATION; DOSE RESPONSE; DRUG EFFECT; HUMAN; MICROBIAL SENSITIVITY TEST; MONTE CARLO METHOD; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS;

ANTITUBERCULAR AGENTS; BETA-LACTAMS; CLAVULANIC ACID; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; HUMANS; MICROBIAL SENSITIVITY TESTS; MONTE CARLO METHOD; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 85028320612     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02039-16     Document Type: Article

References (48)

1. Dheda K, Gumbo T, Maartens G, Dooley KE, McNerney R, Murray M, Furin J, Nardell EA, London L, Lessem E, Theron G, van Helden P, Niemann S, Merker M, Dowdy D, Van Rie A, Siu GK, Pasipanodya JG, Rodrigues C, Clark TG, Sirgel FA, Esmail A, Lin HH, Atre SR, Schaaf HS, Chang KC, Lange C, Nahid P, Udwadia ZF, Horsburgh CR, Jr, Churchyard GJ, Menzies D, Hesseling AC, Nuermberger E, McIlleron H, Fennelly KP, Goemaere E, Jaramillo E, Low M, Jara CM, Padayatchi N, Warren RM. 23 March 2017. The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. Lancet Respir Med https://doi.org/10.1016/S2213-2600(17)30079-6.
2. Dheda K, Gumbo T, Gandhi NR, Murray M, Theron G, Udwadia Z, Migliori GB, Warren R. 2014. Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis. Lancet Respir Med 2:321–338. https://doi.org/10.1016/S2213-2600(14)70031-1.
3. Lange C, Abubakar I, Alffenaar JW, Bothamley G, Caminero JA, Carvalho AC, Chang KC, Codecasa L, Correia A, Crudu V, Davies P, Dedicoat M, Drobniewski F, Duarte R, Ehlers C, Erkens C, Goletti D, Gunther G, Ibraim E, Kampmann B, Kuksa L, de Lange W, van Leth F, van Lunzen J, Matteelli A, Menzies D, Monedero I, Richter E, Rusch-Gerdes S, Sandgren A, Scardigli A, Skrahina A, Tortoli E, Volchenkov G, Wagner D, van der Werf MJ, Williams B, Yew W-W, Zellweger J-P, Cirillo DM. 2014. Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. Eur Respir J 44:23– 63. https://doi.org/10.1183/09031936.00188313.
4. Udwadia ZF, Amale RA, Ajbani KK, Rodrigues C. 2012. Totally drug-resistant tuberculosis in India. Clin Infect Dis 54:579 –581. https://doi.org/10.1093/cid/cir889.
5. Alsaad N, Wilffert B, van Altena R, de Lange WC, van der Werf TS, Kosterink JG, Alffenaar JW. 2014. Potential antimicrobial agents for the treatment of multidrug-resistant tuberculosis. Eur Respir J 43:884–897. https://doi.org/10.1183/09031936.00113713.
6. Hugonnet JE, Tremblay LW, Boshoff HI, Barry CE, III, Blanchard JS. 2009. Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis. Science 323:1215–1218. https://doi.org/10.1126/science.1167498.
7. Bolhuis MS, van der Laan T, Kosterink JG, van der Werf TS, van Soolingen D, Alffenaar JW. 2014. In vitro synergy between linezolid and clarithro-mycin against Mycobacterium tuberculosis. Eur Respir J 44:808–811. https://doi.org/10.1183/09031936.00041314.
8. Pasipanodya J, Gumbo T. 2011. An oracle: antituberculosis pharmacokinetics-pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future. Antimicrob Agents Chemother 55:24–34. https://doi.org/10.1128/AAC.00749-10.
9. Veziris N, Truffot C, Mainardi JL, Jarlier V. 2011. Activity of carbapenems combined with clavulanate against murine tuberculosis. Antimicrob Agents Chemother 55:2597–2600. https://doi.org/10.1128/AAC.01824-10.
10. Tiberi S, Sotgiu G, D’Ambrosio L, Centis R, Abdo Arbex M, Alarcon Arrascue E, Alffenaar JW, Caminero JA, Gaga M, Gualano G, Skrahina A, Solovic I, Sulis G, Tadolini M, Alarcon Guizado V, De Lorenzo S, Roby Arias AJ, Scardigli A, Akkerman OW, Aleksa A, Artsukevich J, Auchynka V, Bonini EH, Chong Marin FA, Collahuazo Lopez L, de Vries G, Dore S, Kunst H, Matteelli A, Moschos C, Palmieri F, Papavasileiou A, Payen MC, Piana A, Spanevello A, Vargas Vasquez D, Viggiani P, White V, Zumla A, Migliori GB. 2016. Comparison of effectiveness and safety of imipenem/ clavulanate- versus meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB. Eur Respir J 47:1758–1766. https://doi .org/10.1183/13993003.00214-2016.
11. Tiberi S, Payen MC, Sotgiu G, D’Ambrosio L, Alarcon Guizado V, Alffenaar JW, Abdo Arbex M, Caminero JA, Centis R, De Lorenzo S, Gaga M, Gualano G, Roby Arias AJ, Scardigli A, Skrahina A, Solovic I, Sulis G, Tadolini M, Akkerman OW, Alarcon Arrascue E, Aleska A, Avchinko V, Bonini EH, Chong Marin FA, Collahuazo Lopez L, de Vries G, Dore S, Kunst H, Matteelli A, Moschos C, Palmieri F, Papavasileiou A, Spanevello A, Vargas Vasquez D, Viggiani P, White V, Zumla A, Migliori GB. 2016. Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB. Eur Respir J 47:1235–1243. https://doi.org/10.1183/13993003.02146-2015.
12. Srivastava S, van Rijn SP, Wessels AM, Alffenaar JW, Gumbo T. 2016. Susceptibility testing of antibiotics that degrade faster than the doubling time of slow-growing mycobacteria: ertapenem sterilizing effect versus Mycobacterium tuberculosis. Antimicrob Agents Chemother 60: 3193–3195. https://doi.org/10.1128/AAC.02924-15.
13. van Rijn SP, van Altena R, Akkerman OW, van Soolingen D, van der Laan T, de Lange WC, Kosterink JG, van der Werf TS, Alffenaar JW. 2016. Pharmacokinetics of ertapenem in patients with multidrug-resistant tuberculosis. Eur Respir J 47:1229 –1234. https://doi.org/10.1183/13993003.01654-2015.
14. Tiberi S, D’Ambrosio L, De Lorenzo S, Viggiani P, Centis R, Sotgiu G, Alffenaar JW, Migliori GB. 2016. Ertapenem in the treatment of multidrug-resistant tuberculosis: first clinical experience. Eur Respir J 47:333–336. https://doi.org/10.1183/13993003.01278-2015.
15. Gumbo T, Dona CS, Meek C, Leff R. 2009. Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs. Antimicrob Agents Chemother 53:3197–3204. https://doi.org/10.1128/AAC.01681-08.
16. Heifets L, Lindholm-Levy P. 1992. Pyrazinamide sterilizing activity in vitro against semidormant Mycobacterium tuberculosis bacterial populations. Am Rev Respir Dis 145:1223–1225.
17. Mitchison DA. 1985. The action of antituberculosis drugs in short-course chemotherapy. Tubercle 66:219 –225. https://doi.org/10.1016/0041-3879(85)90040-6.
18. Gumbo T, Pasipanodya JG, Nuermberger E, Romero K, Hanna D. 2015. Correlations between the hollow fiber model of tuberculosis and therapeutic events in tuberculosis patients: learn and confirm. Clin Infect Dis 61(Suppl 1):S18–S24. https://doi.org/10.1093/cid/civ426.
19. Gumbo T, Pasipanodya JG, Romero K, Hanna D, Nuermberger E. 2015. Forecasting accuracy of the hollow fiber model of tuberculosis for clinical therapeutic outcomes. Clin Infect Dis 61(Suppl 1):S25–S31. https://doi.org/10.1093/cid/civ427.
20. Pasipanodya JG, Nuermberger E, Romero K, Hanna D, Gumbo T. 2015. Systematic analysis of hollow fiber model of tuberculosis experiments. Clin Infect Dis 61(Suppl 1):S10–S17. https://doi.org/10.1093/cid/civ425.
21. Gumbo T, Lenaerts AJ, Hanna D, Romero K, Nuermberger E. 2015. Nonclinical models for antituberculosis drug development: a landscape analysis. J Infect Dis 211(Suppl 3):S83–S95. https://doi.org/10.1093/infdis/jiv183.
22. Akaike H. 1974. A new look at the statistical model identification. IEEE Trans Automat Contr 19:716–723.
23. Swaminathan S, Pasipanodya JG, Ramachandran G, Hemanth Kumar AK, Srivastava S, Deshpande D, Nuermberger E, Gumbo T. 2016. Drug concentration thresholds predictive of therapy failure and death in children with tuberculosis: bread crumb trails in random forests. Clin Infect Dis 63:S63–S74. https://doi.org/10.1093/cid/ciw471.
24. Pasipanodya JG, McIlleron H, Burger A, Wash PA, Smith P, Gumbo T. 2013. Serum drug concentrations predictive of pulmonary tuberculosis outcomes. J Infect Dis 208:1464–1473. https://doi.org/10.1093/infdis/jit352.
25. Chigutsa E, Pasipanodya JG, Visser ME, van Helden PD, Smith PJ, Sirgel FA, Gumbo T, McIlleron H. 2015. Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis. Antimicrob Agents Chemother 59: 38–45. https://doi.org/10.1128/AAC.03931-14.
26. Modongo C, Pasipanodya JG, Magazi BT, Srivastava S, Zetola NM, Williams SM, Sirugo G, Gumbo T. 25 July 2016. Artificial intelligence and amikacin exposures predictive of outcome in multidrug-resistant tuberculosis patients. Antimicrob Agents Chemother https://doi.org/10.1128/AAC.00962-16.
27. Pasipanodya JG, Srivastava S, Gumbo T. 2012. Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy. Clin Infect Dis 55:169–177. https://doi.org/10.1093/cid/cis353.
28. Srivastava S, Pasipanodya JG, Ramachandran G, Deshpande D, Shuford S, Crosswell HE, Cirrincione KN, Sherman CM, Swaminathan S, Gumbo T. 2016. A long-term co-perfused disseminated tuberculosis-3D liver hollow fiber model for both drug efficacy and hepatotoxicity in babies. EBioMedicine 6:126 –138. https://doi.org/10.1016/j.ebiom.2016.02.040.
29. Srivastava S, Pasipanodya JG, Meek C, Leff R, Gumbo T. 2011. Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability. J Infect Dis 204:1951–1959. https://doi.org/10.1093/infdis/jir658.
30. Burkhardt O, Kumar V, Katterwe D, Majcher-Peszynska J, Drewelow B, Derendorf H, Welte T. 2007. Ertapenem in critically ill patients with early-onset ventilator-associated pneumonia: pharmacokinetics with special consideration of free-drug concentration. J Antimicrob Chemother 59:277–284. https://doi.org/10.1093/jac/dkl485.
31. Gumbo T, Angulo-Barturen I, Ferrer-Bazaga S. 2015. Pharmacokinetic-pharmacodynamic and dose-response relationships of antituberculosis drugs: recommendations and standards for industry and academia. J Infect Dis 211 (Suppl 3):S96–S106. https://doi.org/10.1093/infdis/jiu610.
32. Romero K, Sinha V, Allerheiligen S, Danhof M, Pinheiro J, Kruhlak N, Wang Y, Wang SJ, Sauer JM, Marier JF, Corrigan B, Rogers J, Lambers Heerspink HJ, Gumbo T, Vis P, Watkins P, Morrison T, Gillespie W, Gordon MF, Stephenson D, Hanna D, Pfister M, Lalonde R, Colatsky T. 2014. Modeling and simulation for medical product development and evaluation: highlights from the FDA-C-Path-ISOP 2013 workshop. J Pharmacokinet Pharmacodyn 41:545–552. https://doi.org/10.1007/s10928-014-9390-0.
33. Burkhardt O, Majcher-Peszynska J, Borner K, Mundkowski R, Drewelow B, Derendorf H, Welte T. 2005. Penetration of ertapenem into different pulmonary compartments of patients undergoing lung surgery. J Clin Pharmacol 45:659 – 665. https://doi.org/10.1177/0091270005276117.
34. Gumbo T, Chigutsa E, Pasipanodya J, Visser M, van Helden PD, Sirgel FA, McIlleron H. 2014. The pyrazinamide susceptibility breakpoint above which combination therapy fails. J Antimicrob Chemother 69: 2420–2425. https://doi.org/10.1093/jac/dku136.
35. Gumbo T, Pasipanodya JG, Wash P, Burger A, McIlleron H. 2014. Redefining multidrug-resistant tuberculosis based on clinical response to combination therapy. Antimicrob Agents Chemother 58:6111–6115. https://doi.org/10.1128/AAC.03549-14.
36. Zheng X, Zheng R, Hu Y, Werngren J, Davies FL, Mansjo M, Xu B, Hoffner S. 31 May 2016. Determination of minimum inhibitory concentration (MIC) breakpoints for second-line drugs associated with clinical outcomes in multidrug-resistant tuberculosis treatment in China. Antimicrob Agents Chemother https://doi.org/10.1128/AAC.03008-15.
37. Davies Forsman L, Giske CG, Bruchfeld J, Schon T, Jureen P, Angeby K. 2015. Meropenem-clavulanate has high in vitro activity against multidrug-resistant Mycobacterium tuberculosis. Int J Mycobacteriol 4(Suppl 1):S80–S81. https://doi.org/10.1016/j.ijmyco.2014.10.018.
38. Gonzalo X, Drobniewski F. 2013. Is there a place for beta-lactams in the treatment of multidrug-resistant/extensively drug-resistant tuberculosis? Synergy between meropenem and amoxicillin/ clavulanate. J Antimicrob Chemother 68:366–369. https://doi.org/10.1093/jac/dks395.
39. Sotgiu G, D’Ambrosio L, Centis R, Tiberi S, Esposito S, Dore S, Spanevello A, Migliori GB. 2016. Carbapenems to treat multidrug and extensively drug-resistant tuberculosis: a systematic review. Int J Mol Sci 17:373. https://doi.org/10.3390/ijms17030373.
40. Wiskirchen DE, Housman ST, Quintiliani R, Nicolau DP, Kuti JL. 2013. Comparative pharmacokinetics, pharmacodynamics, and tolerability of ertapenem 1 gram/day administered as a rapid 5-minute infusion versus the standard 30-minute infusion in healthy adult volunteers. Pharmaco-therapy 33:266–274. https://doi.org/10.1002/phar.1197.
41. Majumdar AK, Musson DG, Birk KL, Kitchen CJ, Holland S, McCrea J, Mistry G, Hesney M, Xi L, Li SX, Haesen R, Blum RA, Lins RL, Greenberg H, Waldman S, Deutsch P, Rogers JD. 2002. Pharmacokinetics of ertapenem in healthy young volunteers. Antimicrob Agents Chemother 46:3506–3511. https://doi.org/10.1128/AAC.46.11.3506-3511.2002.
42. Teppler H, Gesser RM, Friedland IR, Woods GL, Meibohm A, Herman G, Mistry G, Isaacs R. 2004. Safety and tolerability of ertapenem. J Antimicrob Chemother 53(Suppl 2):ii75–ii81. https://doi.org/10.1093/jac/dkh209.
43. Carlier M, Noe M, De Waele JJ, Stove V, Verstraete AG, Lipman J, Roberts JA. 2013. Population pharmacokinetics and dosing simulations of amoxicillin/clavulanic acid in critically ill patients. J Antimicrob Chemother 68:2600–2608. https://doi.org/10.1093/jac/dkt240.
44. Gumbo T, Louie A, Deziel MR, Liu W, Parsons LM, Salfinger M, Drusano GL. 2007. Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob Agents Chemother 51:3781–3788. https://doi.org/10.1128/AAC.01533-06.
45. Gumbo T, Louie A, Liu W, Brown D, Ambrose PG, Bhavnani SM, Drusano GL. 2007. Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations. Antimicrob Agents Chemother 51: 2329–2336. https://doi.org/10.1128/AAC.00185-07.
46. Srivastava S, Musuka S, Sherman C, Meek C, Leff R, Gumbo T. 2010. Efflux-pump-derived multiple drug resistance to ethambutol monotherapy in Mycobacterium tuberculosis and the pharmacokinetics and pharmacodynamics of ethambutol. J Infect Dis 201:1225–1231. https:// doi.org/10.1086/651377.
47. Musuka S, Srivastava S, Siyambalapitiyage Dona CW, Meek C, Leff R, Pasipanodya J, Gumbo T. 2013. Thioridazine pharmacokinetic-pharmacodynamic parameters “wobble” during treatment of tuberculosis: a theoretical basis for shorter-duration curative monotherapy with congeners. Antimicrob Agents Chemother 57: 5870–5877. https://doi.org/10.1128/AAC.00829-13.
48. van Rijn SP, Wessels AM, Greijdanus B, Touw DJ, Alffenaar JW. 2014. Quantification and validation of ertapenem using a liquid chromatography-tandem mass spectrometry method. Antimicrob Agents Chemother 58: 3481–3484. https://doi.org/10.1128/AAC.00025-14.